Funded Startups in Watertown
Watertown’s most recent disclosed rounds concentrate in biotech and data-like sectors, with biotechnology appearing 18 of 29 rows (Parallel Bio $21M on 202…
Watertown’s most recent disclosed rounds concentrate in biotech and data-like sectors, with biotechnology appearing 18 of 29 rows (Parallel Bio $21M on 2025-06-11; The Cadmus Group is the main non-biotech heavyweight at $150M on 2024-11-20). The largest disclosed round is The Cadmus Group’s $150M (2024-11-20), which dwarfs every other disclosed amount in the table except for Lyndra Therapeutics at $101M (2023-12-21) and Lyra Therapeutics at $101M (2022-04-08). Several entries also cluster tightly in late 2024: from 2024-11-20 (The Cadmus Group $150M) through 2024-07-31 (Extrasense Technologies, undisclosed), multiple large financings land within that same mid/late-year window, including Corner Therapeutics’ $54M (2024-04-18) and Syncell’s $15M (2024-12-11). Stage and disclosure are mixed: “Series Unknown” appears 14 of 29 rows, and “undisclosed” amounts appear 3 of 29 rows, while disclosed amounts range from $2M (SQZ Biotech, Grant on 2022-03-21) up to $175M (Affini-T Therapeutics, Venture - Series Unknown on 2022-03-22).
Most recent rounds
29 shownRelated listings
Frequently asked
What stands out as the biggest and smallest disclosed rounds in Watertown, and how extreme is the spread?
The largest disclosed amount is Affini-T Therapeutics at $175M (Venture - Series Unknown, 2022-03-22); the next-largest disclosed amounts include The Cadmus Group at $150M (2024-11-20) and Seismic Therapeutic at $121M (2023-12-04). The smallest disclosed amount is SQZ Biotech at $2M (Grant, 2022-03-21), making the disclosed range very wide despite a biotech-heavy list.
Does the list cluster in time, especially around late 2024?
Yes. Multiple rounds fall within a narrow late-2024 window, including The Cadmus Group at $150M on 2024-11-20, Syncell at $15M on 2024-12-11, Portal at $7M on 2024-12-19, and Corner Therapeutics at $54M on 2024-04-18. Even with gaps, the densest disclosed/dated activity spans roughly mid-2024 to year-end 2024.
Which sectors are over-represented among these Watertown entries?
Biotechnology dominates at 18 of 29 rows, far outnumbering other categories like Data and Analytics (4 rows: The Cadmus Group $150M on 2024-11-20, Adams Clinical undisclosed on 2024-05-21, Via Separations $10M on 2022-11-22, plus one more). Non-biotech outliers also exist in adjacent areas, such as Hardware (C2Sense, undisclosed on 2024-04-09) and Energy (WiTricity $63M on 2022-08-09).
How much of the stage mix is unclear in this dataset?
“Series Unknown” accounts for 14 of 29 rows, and “undisclosed” amounts appear in 3 of 29 rows (Extrasense Technologies on 2024-07-31; Adams Clinical on 2024-05-21; C2Sense on 2024-04-09). That combination means many entries can’t be compared by both stage and disclosed size, even when dates are specific.
Are any recent rounds (e.g., last 90 days in the table) concentrated in particular sectors or stages?
Using the table’s most recent date (Parallel Bio on 2025-06-11), the last-90-days window includes Parallel Bio $21M (2025-06-11) and EnPlusOne Biosciences $10M (Series Unknown, 2025-02-19). Both are biotechnology, and at least one (EnPlusOne) carries a “Series Unknown” label, reinforcing the sector concentration despite stage ambiguity.
Which outliers are worth extra scrutiny beyond “biggest round” comparisons?
The Cadmus Group’s $150M (Data and Analytics, 2024-11-20) is a major sector outlier relative to the biotech concentration, and its size sits near the top of all disclosed amounts. On the small end, the $100K Dynamo Software round (Private Equity, 2021-09-09) is an extreme low disclosed outlier compared with biotech rounds like Entact Bio at $81M (2022-12-06) and WiTricity at $63M (2022-08-09).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.